Misra S. . .Carcinoma of the Gallbladder.” The Lancet Oncology. , 03(2003) : 01021-0.
Levy A.D. . .. Gallbladder Carcinoma: RadiologicPathologic Correlation.” Radiographics, 21(2001) : 295-314.
Sharma A. .2017 .. Gallbladder Cancer Epidemiology, Pathogenesis and Molecular Biology: An Update.” Asian Pacific Journal of Cancer Prevention, 18(2017) : 2339-2349.
Aretxabala De,X. De .2005 .Gallbladder Cancer: An Analysis of a Series of 139 Patients with Invasion Restricted to the Subserosal Layer. ” Journal of Gastrointestinal Surgery, 09(2006) : 186-192.
Roa I. . .Preneoplastic Lesions in Gallbladder Cancer. ” Journal of Surgical Oncology, 93(2006) : 615-623.
Lazcano-Ponce E.C. . .Epidemiology and Molecular Pathology of Gallbladder Cancer. CA: A Cancer Journal for Clinicians, 51(2001) : 349-364.
Patel T. .2002 .Worldwide Trends in Mortality from Biliary Tract Malignancies. ” BMC Cancer, 2 : 1471.
Kumari N.,January- N. .2014 .Mutation Profiling in Gallbladder Cancer in Indian Population. Indian Journal of Pathology and Microbiology, 57(1) : 130849-4929.
Saetta A.A. . .Mutational Analysis of BRAF in Gallbladder Carcinomas in Association with K-ras and p53 Mutations and Microsatellite Instability. Virchows Archiv, 445(2004) : 004-182.
Henson D.E. . .Carcinomas of the Pancreas, Gallbladder, Extrahepatic Bile Ducts and Ampulla of Vater Share a Field for Carcinogenesis: A Population-Based Study. Archives of Pathology & Laboratory Medicine, 133(2009) : 67-71.
Sasatomi E. . .Precancerous Conditions of Gallbladder Carcinoma: Overview of Histopathologic Characteristics and Molecular Genetic Findings. ” Journal of Hepato-BiliaryPancreatic Surgery, 7(2000) : 556-567.
Nakanuma Y. . .:AID-JEMT2>3.0. Microscopy Research and Technique, 38(19970915) : 2-0029.
Pilgrim C.H. .2013 .Modern Perspectives on Factors Predisposing to the Development of Gallbladder Cancer. ” HPB, 15(11) : 839-844.
Mondal S.K.,October -December .2017 .Histopathological Study of Gallbladder Carcinoma and Its Mimics with Role of Carcinoembryonic Antigen Immunomarker in Resolving Diagnostic Difficulties. Indian Journal of Medical and Paediatric Oncology, 230(4) : 15-415.
Chang H.J. . .Loss of Heterozygosity in Dysplasia and Carcinoma of the Gallbladder. ” Modern Pathology, 12(1999) : 00000478-769.
Wan X. .2017 .Gallbladder Papillary Neoplasms Share Pathological Features with Intraductal Papillary Neoplasm of the Bile Duct. ” Oncotarget, 8(19) : 31532-31539.
Wu X.S. . .Expression of Homeodomain Protein CDX2 in Gallbladder Carcinomas. ” Journal of Cancer Research and Clinical Oncology, 131(2005) : 271-278.
Kuraguchi M. .2006 .Adenomatous Polyposis Coli (APC) Is Required for Normal Development of Skin and Thymus. PLoS Genetics, 0020146(9) : .
Sugimachi K. . .The Role of Overexpression and Gene Amplification of Cyclin D1 in Intrahepatic Cholangiocarcinoma. ” Journal of Hepatology, 8278(01) : 0078-6.
Kanthan R. .2015 .Gallbladder Cancer in the 21st Century. ” Journal of Oncology, : .
Page M.J. .2021 .. The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews.” BMJ, 372 : .
Higgins J.P.T. .2024 .. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.5, updated August, : .
Wells G.A. .2022 .The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Non-Randomised Studies in MetaAnalyses. , : .
DerSimonian N.,Laird N. . .. Meta-Analysis in Clinical Trials.” Controlled Clinical Trials, 7(86) : 90046-2.
Higgins J.P. .2003 .. Measuring Inconsistency in MetaAnalyses.” BMJ, 327(7414) : 557-560.
Roa I.,Patterns Spread .1999 .Gallbladder Cancer in a High Risk Area: Morphological Features. ” Hepatogastroenterology, 46(27) : 1540-1546.
Roa J.C. .2011 .. Squamous Cell and Adenosquamous Carcinomas of the Gallbladder: Clinicopathological Analysis of 34 Cases Identified in 606 Carcinomas.” Modern Pathology, 68(2011) : 1069-1078.
Ghosh M.,January -February .2013 .p53 and Beta-Catenin Expression in Gallbladder Tissues and Correlation with Tumor Progression in Gallbladder Cancer. Saudi Journal of Gastroenterology, 19(1) : 105922-3767.
Nakanuma Y.,Nagtegaal Y. .2019 .Cholangiocarcinoma.” WHO Classification of Tumours: Digestive System Tumours. , : 254-263.
Duffy A. . .Gallbladder Cancer (GBC): 10-Year Experience at Memorial Sloan-Kettering Cancer Centre (MSKCC). ” Journal of Surgical Oncology, 98(2008) : 485-489.
Adsay N.V. .2012 .Pathologic Staging of Pancreatic, Ampullary, Biliary and Gallbladder Cancers: Pitfalls and Practical Limitations of the Current AJCC/UICC TNM Staging System and Opportunities for Improvement.” Seminars in Diagnostic Pathology. , 04(2012) : 127-141.
Stuart L.N. . .Analytic Validation of Immunohistochemistry Assays: New Benchmark Data from a Survey of 1085 Laboratories.” Archives of Pathology & Laboratory Medicine. , 141(2017) : 1255-1261.
Sirohi B. .2015 .Use of Gemcitabine-Based Chemotherapy in Indian Patients with Gallbladder Cancer. Future Oncology, 11(11) : 1575-1585.
Zou R.Q. .2022 .Comparison of Clinicopathological Characteristics of Mucinous Adenocarcinoma and Conventional Adenocarcinoma of Gallbladder. Asian Journal of Surgery, 03(2023) : 283-290.
Bhoge A. .2017 .Immunohistochemical Study of MUC1 and MUC5AC Expression in Gall Bladder Lesions. ” Journal of Clinical and Diagnostic Research, 11(7) : EC12-EC16.
Kong F.H. .2025 .. Mixed Adenoneuroendocrine Carcinoma of the Gallbladder: A Case Report and Literature Review.” Frontiers in Oncology, 1584744 : .
Benson A.B.,NCCN A.B. .2021 .Clinical Practice Guidelines in Oncology. ” Journal of the National Comprehensive Cancer Network, 0022(2021) : 541-565.
Corti F. .2018 .Targeting the PI3K/AKT/mTOR Pathway in Biliary Tract Cancers: A Review of Current Evidences and Future Perspectives.” Cancer Treatment Reviews. , 11 : 45-55.
Paweletz C.P. .2001 .. Reverse Phase Protein Microarrays Which Capture Disease Progression Show Activation of ProSurvival Pathways at the Cancer Invasion Front.” Oncogene, 1204265(16) : 1981-1989.